Planned Management Team Changes

Amsterdam, The Netherlands, December 8, 2016 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces that Arthur Lahr will join Kiadis Pharma on January 1, 2017 as Chief Operating Officer (COO) and Chief Executive Officer (CEO) des­ig­nate. The search for a COO and CEO des­ig­nate has been co-led by the Company’s CEO, Manfred Rüdiger, and the Company’s Supervisory Board. Following five years as CEO, and as the Company is advanc­ing into a late stage clin­i­cal/pre-com­mer­cial­iza­tion phase, Dr. Rüdiger will hand over his respon­si­bil­i­ties as CEO on April 1, 2017 as part of a planned and thor­ough­ly exe­cut­ed suc­ces­sion plan.

Manfred Rüdiger said: “My deci­sion to step down from Kiadis Pharma next year is tak­en because I want to spend more time with my fam­i­ly, who are all liv­ing out­side of The Netherlands. I am very proud of what my team has achieved dur­ing my five years at Kiadis Pharma and feel that the Company is in strong health mov­ing into a new phase and thus now is a decent time to depart. I am pleased that Arthur Lahr has tak­en the deci­sion to join the Company and I am very con­fi­dent that he is ide­al­ly posi­tioned to take Kiadis Pharma for­ward into its next phase of devel­op­ment.

Manfred Rüdiger joined Kiadis Pharma in 2011 and has since then redi­rect­ed its devel­op­ment into a late stage clin­i­cal/pre-com­mer­cial­iza­tion com­pa­ny which will ini­ti­ate a piv­otal Phase III transat­lantic tri­al immi­nent­ly. Dr. Rüdiger also guid­ed the Company through var­i­ous financ­ings lead­ing to the Company’s IPO on Euronext Amsterdam and Brussels in 2015, rais­ing EUR 34.7 mil­lion.

Arthur Lahr joins Kiadis Pharma with sig­nif­i­cant expe­ri­ence from with­in the health­care sec­tor. Most notably, Mr. Lahr was Chief Strategy Officer and mem­ber of the Management Committee at Crucell from 2001 until its acqui­si­tion by Johnson & Johnson for USD 2.4 bil­lion in 2011. At Crucell, a Euronext and NASDAQ list­ed ful­ly inte­grat­ed glob­al vac­cine com­pa­ny with USD 500 mil­lion in sales, Mr. Lahr held vary­ing respon­si­bil­i­ties includ­ing for busi­ness devel­op­ment, strat­e­gy, M&A, US and EU mar­ket­ing & sales, and the ful­ly inte­grat­ed pro­tein busi­ness unit. Prior to that, Mr. Lahr was a Consultant at McKinsey & Company between 1994 and 2001 in Amsterdam and New York. He began his career as an Engineer at Unilever and has an MSc in Applied Physics from the University of Delft and an MBA from INSEAD.

Mark Wegter, Chairman of the Supervisory Board, com­ment­ed: “Manfred has done a tremen­dous job over the past five years devel­op­ing Kiadis Pharma into a pre-com­mer­cial­iza­tion bio­phar­ma­ceu­ti­cal com­pa­ny that remains firm­ly on course to file for mar­ket­ing autho­riza­tion with the European Medicines Agency (EMA) for ATIR101™ in blood can­cers in Q1 2017. The list­ing on Euronext in 2015 would not have hap­pened with­out the lead­er­ship and ded­i­ca­tion of Manfred. I have worked very close­ly with Manfred over many years and now know him as a great per­son who has done a phe­nom­e­nal job. On behalf of the Supervisory Board and all of the Company’s employ­ees, I want to express my grat­i­tude and appre­ci­a­tion for all his hard work and accom­plish­ments for Kiadis Pharma. The Supervisory Board looks for­ward to work­ing with Arthur in a sim­i­lar fash­ion as we pre­pare to ini­ti­ate the piv­otal Phase III tri­al for ATIR101™. Arthur has very rel­e­vant expe­ri­ence in R&D, busi­ness devel­op­ment and com­mer­cial­iza­tion of bio­phar­ma­ceu­ti­cals and is ide­al­ly posi­tioned to strength­en the man­age­ment team as COO and CEO des­ig­nate. The peri­od until Manfred’s offi­cial depar­ture as per April 1, 2017 will allow him to hand over in a seam­less way.”

Arthur Lahr, incom­ing COO and CEO des­ig­nate, said: “I am very pleased to join Kiadis Pharma at this impor­tant time in its evo­lu­tion. Under Manfred’s strong lead­er­ship the Company has made tremen­dous progress, and the poten­tial of the promis­ing ATIR prod­uct port­fo­lio is sig­nif­i­cant. I enter Kiadis Pharma with great excite­ment and look for­ward to work­ing close­ly with Manfred and the team to take the Company into its next stage of devel­op­ment, and fore­most to make a real dif­fer­ence for patients.”

Leave a Reply

Your email address will not be published. Required fields are marked *